



IAEA

Atoms for Peace

الوكالة الدولية للطاقة الذرية

国际原子能机构

International Atomic Energy Agency

Agence Internationale de l'énergie atomique

Международное агентство по атомной энергии

Organismo Internacional de Energía Atómica

National Liaison Officer

Vienna International Centre, PO Box 100, 1400 Vienna, Austria

Phone: (+43 1) 2600 • Fax: (+43 1) 26007

Email: Official.Mail@iaea.org • Internet: <http://www.iaea.org>

In reply please refer to: RER6035 – EVT1701169

Dial directly to extension: (+431) 2600-26306

2017-05-30

Subject: Invitation to a Regional Training Course on Theranostics and Molecular Radiotherapy, Brussels, Belgium, 2-6 October 2017

Dear National Liaison Officer,

I am pleased to invite you to send nominations of suitable candidates to participate in the above-mentioned training course under the framework of TC Project RER/6/035 – Strengthening Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) and Positron Emission Tomography (PET/CT) Hybrid Imaging Applications for Diagnosis of Chronic Diseases, including Cancer. The purpose of the training course and related information are outlined in the attached Prospectus.

For candidates who are selected by the IAEA, the IAEA will cover the cost of return international travel from the home country to Brussels, Belgium and provide a stipend for the duration of the training course in line with IAEA rules and procedures.

Please submit nominations to the IAEA online through the Technical Cooperation Department's InTouch system (<http://intouch.iaea.org>). Only if this is not possible, nominations may be submitted on the Nomination Form for Training Course available on the IAEA website: <http://www.iaea.org/technicalcooperation/How-to-take-part/train-course/index.html>. Completed forms should be endorsed by relevant national authorities and sent to the Programme Management Officer for this project, Ms Mayumi Yamamoto (IAEA Official Fax: +43-1-26007 or E-Mail Official.Mail@iaea.org), through the official channels, i.e. the designated National Liaison Office for IAEA matters, not later than 10 July 2017.

Yours sincerely,

Martin Krause

Director

Division for Europe

Department of Technical Cooperation

Enclosure: Prospectus

International Atomic Energy Agency

Regional Training Course on Theranostics and Molecular Radiotherapy

PROSPECTUS

- Project Number & Title:** RER/6/035 Strengthening Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) and Positron Emission Tomography (PET/CT) Hybrid Imaging Applications for Diagnosis of Chronic Diseases, including Cancer.
- Place (City, Country):** Brussels, Belgium
- Dates:** 2-6 October 2017
- Deadline for Nominations:** 10 July 2017
- Organizers:** The International Atomic Energy Agency (IAEA) in cooperation with the Government of Belgium through the Institute Jules Bordet, Brussels, Belgium.
- Host Country Organizer:** Mr Patrick Flamen (Dr.)
Department of Nuclear Medicine
Molecular Imaging and Radionuclide Therapy
Institute Jules Bordet
Rue Heger-Bordetstraat 1
B-1000 Brussels, Belgium
Tel.: 0032 (0) 2 541 32 40
Fax: 0032 (0) 2 541 32 24
E-mail: patrick.flamen@bordet.be
- Language:** English
- Purpose:** The objectives of this regional course will be to train nuclear medicine physicians with consolidated experience in therapeutic Nuclear Medicine. Participants will gain skills and competences which will enable them to enhance their practices.
- Expected Output(s):** Participants trained, level of knowledge upgraded.
- Scope and Nature:** The training course covers the fundamental principles and application of therapeutic nuclear medicine, specifically, nuclear medicine techniques in the treatment of thyroid cancer, prostate cancer and other cancer types. These lectures should provide theoretical grounding in the improvement of nuclear medicine Services.

The experts will discuss the clinical utility and relative value with emphasis on the protocols to be used in the above conditions which will be one of the core learning points of this training course.

Format: Lectures and Interactive discussion sessions covering approaches in Targeted Radionuclide Therapy from streamlined and emerging approaches. These lectures should provide theoretical grounding in the improvement of therapeutic Nuclear medicine Services to achieve the following:

- a) Review the different established and emerging therapeutic nuclear medicine protocols and nuclear techniques in the evaluation and management of thyroid cancer, Prostate cancer and other cancer types using I-131 and other radiopharmaceuticals.
- b) Comprehensive knowledge of epidemiology, causes, risk factors, clinical manifestations/symptoms in thyroid cancer, prostate cancer and others.
- c) Differentiate and analyse the different protocols used in therapeutic nuclear medicine procedures including the role of hybrid imaging.
- d) Explore the role of targeted radionuclide therapies into the clinical practice in IAEA Member States.
- e) Comprehensive knowledge on the different medical physicists aspects of targeted radionuclide therapy, including but not limited to internal dosimetry, radiation safety, quantification, advances in gamma camera SPECT/CT systems and PET/CT imaging, accreditation of PET systems, and Quality Assurance and Quality Control.

Participation: The training course is open to a maximum of 25 participants from countries that participate in the RER/6/035 project and need assistance in training staff for Targeted Radionuclide Therapy.

The target countries are: Armenia, Azerbaijan, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Estonia, Georgia, Greece, Hungary, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Montenegro, Poland, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Tajikistan, The former Yugoslav Republic of Macedonia, Ukraine and Uzbekistan.

Participants' Qualification: The nominees should be qualified Nuclear Medicine Physicians. Candidates should be working currently in nuclear medicine or radiology departments, with strong commitment to provide radionuclide therapy.

Nominations of oncologists who wish to have exposure to nuclear medicine applications with a view of implementing in their practices are also acceptable.

Nomination Procedure: Nominations should be submitted to the IAEA online through the Technical Cooperation Department's InTouch system (<http://intouch.iaea.org>). Should

this not be possible, nominations may be submitted on the standard IAEA Nomination Form for Training Courses (available from the IAEA website: <http://www.iaea.org/>). Completed forms should be endorsed by the relevant national authorities and returned to the Agency through the normal official channels, i.e. the designated National Liaison Office for IAEA matters.

The completed nomination forms should be sent to the Programme Management Officer for this project, Ms Mayumi Yamamoto, through IAEA Official Fax (+43-1-26007) or E-Mail (Official.Mail@iaea.org), not later than **10 July 2017**. Nominations received after this date or which have not been routed through the established official channels cannot be considered.

**Administrative
and Financial
Arrangements:**

Nominating Governments will be informed in due course of the names of the candidates who have been selected and will, at that time, be given full details of the procedures to be followed with regard to administrative and financial matters.

Selected participants from countries eligible to receive technical assistance will be provided with a round trip economy class air ticket from their home countries to Brussels (BELGIUM), and a stipend sufficient to cover the cost of their accommodation, food and minor incidentals. Shipment of accumulated training course materials to the participants' home countries is not the responsibility of the IAEA.

The organizers of the training course do not accept liability for the payment of any cost or compensation that may arise from damage to or loss of personal property, or from illness, injury, disability or death of a participant while he/she is travelling to and from or attending the course, and it is clearly understood that each Government, in nominating participants, undertakes responsibility for such coverage. Governments would be well advised to take out insurance against these risks.